92例多发性骨髓瘤合并肾功能不全患者的临床分析
被引量:2
摘要
多发性骨髓瘤(MM)是一种恶性浆细胞疾病,浆细胞单克隆增殖产生的免疫球蛋白及轻链引起的肾功能损害在临床上主要表现为肾功能不全,预后较不伴有肾功能不全的骨髓瘤患者差,是造成骨髓瘤患者死亡的最常见原因之一。我们回顾性分析了92例MM合并肾功能不全的患者资料,旨在分析其临床特征及预后。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2010年第9期629-631,共3页
Chinese Journal of Hematology
参考文献10
-
1张之南.血液病诊断及疗效标准.3版.北京:科学出版社,2008.106-113.
-
2Chan DT,Craig K,Donovan K,et al.Myeloma renal disease:presentation and outcome.Nephron Clin Pract,2006,104:126-131.
-
3Montseny JJ,Kleinknecht D,Meyrier A,et al.Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies.Nephrol Dial Transplant,1998,13:1438-1445.
-
4Bladé J,Rosinol L.Renal,hematologic and infectious complications in multiple myeloma.Best Pract Res Clin Haematol,2005,18:635-652.
-
5Montagut C,Bosch F,Villela L,et al.Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.Leuk Lymphoma,2004,45:1711-1712.
-
6Blade J,Fernandez-Llama P,Bosch F,et al.Renal failure in multiple myeloma:presenting features and predictors of outcome in 94 patients from a single institution.Arch Intern Med,1998,158:1189-1193.
-
7Knudsen LM,Hjorth M,Hippe E,et al.Renal failure in myeloma reversibility and impact on the prognosis.The Nordic Myeloma Study Group.Eur J Haematol,2000,65:175-181.
-
8Bladé J,Sonneveld P,San Miguel JF,et al.Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma:efficacy and safety in patients with renal function impairment.Clin Lympgoma Myeloma,2008,8:352-355.
-
9Greipp PR,San Miguel J,Durie BG,et al.International staging systerm for multiple myeloma.J Clin Oncol,2005,23:3412-3420.
-
10李娟,赵莹,罗绍凯,黄蓓晖,张国材,彭爱华,郑冬,苏畅,许多荣,童秀珍,谷景立,丁艳.223例新诊断多发性骨髓瘤临床特点及疗效分析[J].中华医学杂志,2008,88(30):2140-2143. 被引量:21
二级参考文献8
-
1麦玉洁,邱录贵,李睿,靳风艳,白洁,万长春,王建祥,季林祥,肖志坚,钱林生.432例多发性骨髓瘤临床分析[J].白血病.淋巴瘤,2004,13(4):198-201. 被引量:27
-
2陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量:44
-
3武永吉.多发性骨髓瘤//张之南,沈悌,血液病诊断及疗效标准,3版.北京:科学出版社,2007:232-235.
-
4Blade J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. european group for blood and marrow transplant. Br J Haematol, 1998,102 : 1115-1123.
-
5Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78:21-33.
-
6Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol, 1994, 12:2398-2404.
-
7Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol, 1991,47:262-267.
-
8庄俊玲,武永吉,钟玉萍,何坚,沈悌,张之南.多发性骨髓瘤218例临床分析[J].中国实用内科杂志,2004,24(2):108-110. 被引量:61
共引文献25
-
1王银平,蔡颖,王建中,刘贵建,沈军,龙红,黄泛舟,朱平,邢宝利,崔巍,史慧琳.间断发热伴白细胞异常升高[J].中华检验医学杂志,2008,31(11):1302-1305.
-
2冯建军,杨林花,陈剑芳,刘秀娥,来晓炜.血小板减少性紫癜血小板特异性抗体和促血小板生成素检测的临床意义[J].中国药物与临床,2009,9(4):272-274. 被引量:6
-
3赵莹,李娟,曾丽金,丁艳,王荷花,郑冬,童秀珍,张国材.硼替佐米联合地塞米松治疗多发性骨髓瘤疗效及影响因素分析[J].中国实用内科杂志,2009,29(6):526-528. 被引量:6
-
4彭嵘,侯健,傅卫军,袁振刚,张春阳,闫岩.34例IgD型多发性骨髓瘤临床特点分析[J].中华血液学杂志,2011,32(3):204-205. 被引量:12
-
5李美玲,杨林花,朱镭,张莉.T淋巴细胞亚群在特发性血小板减少性紫癜患者中的表达及意义[J].中国药物与临床,2011,11(4):408-409. 被引量:9
-
6陈美兰,李娟,刘俊茹,黄蓓晖,郑冬,谷景立.IgD型多发性骨髓瘤18例临床特征和生存分析[J].中国实用内科杂志,2011,31(11):868-870. 被引量:4
-
7解文君,王蓓,李俊英,蔡学麟,张志灵,郑卫红,马新娟.儿童造血干细胞移植预处理期不良反应的观察与护理[J].中华现代护理杂志,2012,18(16):1922-1924. 被引量:3
-
8邹外一,李娟.造血干细胞移植治疗多发性骨髓瘤[J].临床血液学杂志,2012,25(4):410-413. 被引量:6
-
9杨慧华,庞辉,唐晓钰,刘文海.多发性骨髓瘤29例误诊原因讨论[J].临床误诊误治,2012,25(7):25-27. 被引量:9
-
10戴益琛,朱小三,傅育卡.以黑便为首发症状的多发性骨髓瘤1例[J].临床军医杂志,2013,41(2):121-121.
同被引文献30
-
1Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma[J]. Blood Cancer J,2015,5(3)..e296.
-
2Heher EC, Rennke HG, Laubach JP, et al. Kidney disease and multiple myeloma[J]. Clin J Am Soc Nephrol,2013,8 (11) :2007 2017.
-
3Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoelonal IgG deposits [J]. J Am Soc Nephrol, 2009,20(9) : 2055-2064.
-
4Findlay M, Isles C. Clinical companion in nephrology[M]. Switzerland : Springer, 2015 : 71-75.
-
5Findlay M, Isles C. Overview of chronic kidney disease [ M]. Switzerland : Springer, 2015 : 101-106.
-
6Nasr, SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease : a report of 64 patients from a single institution[J]. Clin J Am Soc Nepbrol, 2012,7(2) :231 239.
-
7Dimopoulos MA, Terpos E, Chanan Khan A, et al. Renal impairment in patients with multiple myeloma:a consen sus statement on behalf of the International Myeloma Working Group[J]. J Clin Oncoi, 2010, 28 (33) : 4976 4984.
-
8Sarkozi R, Perco P, Hochegger K, et al. Bortezomib in duced survival signals and genes in human proximal tubu lar cells[J]. J Pharmacol Exp Ther, 2008,327 (3) : 645- 656.
-
9Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal fail- ure with bortezomib-based regimens[J]. Leukemia Lyre phoma,2008,49(5) :890 895.
-
10Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment:cohort analysis of the phase m VISTA study[J]. J Clin Oncol, 200{,, 27 (36) :6086 6093.
二级引证文献23
-
1艾国.两种方案治疗多发性骨髓瘤近期疗效分析[J].海南医学,2017,28(16):2612-2614. 被引量:13
-
2何凤娥,刘依霜,陈应红.血浆置换在多发性骨髓瘤患者中的应用效果观察[J].全科口腔医学电子杂志,2019,6(23):145-146. 被引量:2
-
3刘芳,余艳丽,郭彩利.尿NAG联合血清β2-MG、Cys-C对多发性骨髓瘤患者肾功能损伤的预测价值[J].临床误诊误治,2020,33(11):91-95. 被引量:5
-
4黄昭萍,杨灿华.老年多发性骨髓瘤合并肾损伤患者的病理特征及危险因素分析[J].中国医药,2021,16(3):417-421. 被引量:10
-
5刘萌萌,王喜凤,刘兴华,刘鹏,王轶娟,刘灵,魏丽.表现为间质性肾炎的骨髓瘤肾损伤临床病理特征分析[J].中国临床新医学,2021,14(6):586-589.
-
6俞玲.多发性骨髓瘤患者肾损伤预测模型的构建[J].广东医学,2021,42(7):802-805. 被引量:6
-
7庄妮拉,詹文丽,莫泰金,李小淦,曾祥兴,王秋香.血清IL-9、IL-18及IL-32水平对多发性骨髓瘤患者肾损伤的诊断价值[J].临床肾脏病杂志,2021,21(7):556-561. 被引量:5
-
8曲璟,肖斌,李林海,曾涛.多发性骨髓瘤合并肾损伤的实验室特征[J].实用医学杂志,2021,37(15):2003-2006. 被引量:7
-
9高阳,朱玉.多发性骨髓瘤患者合并感染的危险因素分析及控制[J].实用癌症杂志,2021,36(11):1847-1850. 被引量:3
-
10赵越,黄垚.骨髓瘤患者血浆Ghrelin水平与免疫功能的变化研究[J].中国肿瘤临床与康复,2021,28(12):1477-1480. 被引量:1
-
1沈卫章,田春艳,张凤春,徐文,姜玉珍,王秀丽,王春红.多发性骨髓瘤82例误诊分析[J].白血病.淋巴瘤,2002,11(6):357-358. 被引量:10
-
2肖志坚,秦铁军.反应停加联合化疗治疗浆细胞白血病一例[J].中华血液学杂志,2002,23(6):336-336. 被引量:2
-
3谢亚萍,钱劼靖,童茵,钱文斌,孟海涛,麦文渊.硼替佐米 地塞米松治疗复发 难治性多发性骨髓瘤临床分析[J].浙江临床医学,2008,10(4):475-476. 被引量:1
-
4杨辉,尹松梅,聂大年,谢双峰,马丽萍.多发性骨髓瘤85例临床报告[J].临床误诊误治,2005,18(8):572-573. 被引量:7
-
5屈建良,唐晓红.多发性骨髓瘤合并肾功能不全患者的临床特点[J].实用癌症杂志,2016,31(5):836-838. 被引量:1
-
6牛俊杰,裴福生,王平,钱裕民,王冠宙,王巧玲,胡治黄,曲垣瑞.老年人多发性骨髓瘤35例临床研究[J].实用医技杂志,2004,11(05A):617-618.
-
7罗琳,李凯丽,刘尚勤.多发性骨髓瘤合并肾功能不全的临床分析[J].临床肾脏病杂志,2013(6):254-257. 被引量:3
-
8陈林,葛付涛,沙辉,叶龙,赵松,牛丰.血清长链非编码RNA CRNDE-h、GAS5检测在预测多发性骨髓瘤预后中的价值分析[J].中国实验诊断学,2016,20(5):796-799. 被引量:8
-
9饶小英.多发性骨髓瘤20例误诊分析[J].实用临床医学(江西),2005,6(11):61-61. 被引量:3
-
10罗军德,张晓,毕开德,张云平,邓亚.多发性骨髓瘤的影像诊断[J].西南军医,2008,10(5):77-78. 被引量:3